ClinicalTrials.gg
CompletedNCT02109991Updated Dec 8, 2017

Safety, Tolerability and Performance Profile of the Colospan Device CG-100 in Patients Undergoing Colorectal Surgery

An interventional study of CG-100 device in Gastrointestinal Anastomosis, sponsored by Colospan Ltd.. Completed at 8 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-08.

Sponsored by Colospan Ltd. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the CG-100 device, a single use, temporary intraluminal bypass device,intended to reduce contact of fecal content with an anastomotic site, following colorectal surgery (open or laparoscopic).

02

Conditions studied

  • Gastrointestinal Anastomosis
03

In context

Lead sponsor

Colospan Ltd. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient is scheduled to undergo an elective colorectal surgery (open or laparoscopic) which will require the creation of an anastomosis, maximally 20 cm proximal from the anal verge
  • The patient is willing to comply with protocol-specified follow-up evaluations
  • The patient signed

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing female subjects
  • Patient surgical treatment is acute (not elective)
  • Patient has infections at the time of intervention
  • Major surgical or interventional procedures within 30 days prior to this study or planned surgical or interventional procedures within 30 days of entry into this study
  • Patients with ASA () classification > 3
  • diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, local or systemic infection, ischemic bowel, carcinomatosis or extensively spread inflammatory bowel disease
  • Patient is participating in another clinical trial within 30 days of screening
  • Patient has been taking regular medication in the last 6 months
  • to general anesthesia
  • Patient has preexisting sphincter problems or evidence of extensive local disease in the pelvis
  • Internal diameter lumen of the colon is smaller than 25 mm or larger than 34 mm
  • Blood loss (> 500 cc)
  • Leak test failure during surgery
  • Any condition or surgical incidence where the device deployment can jeopardize the patient's safety or interferes with study outcome per the discretion of the investigator
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    CG-100 device

    Device: CG-100 device

Interventions

  • DeviceCG-100 device

    Colorectal surgery performed per standard of care with deployment of the CG-100 device in the anastomosis site

06

What researchers measure

Primary outcomes

  1. Rate of adverse events, and device related complications

    Time frame: During surgical procedure and up to 30 days (+/- 5)

Secondary outcomes

  1. Occurrence of anastomotic leakage when the CG-100 is used

    Time frame: Up until device removal day (10 days +/-1)

  2. Position of the device (internal sheath)

    Time frame: Device removal day (10 days +/-1)

  3. Assessment of the device's application technique ease of placement and extraction of the device performance

    Time frame: Device removal day (10 days +/-1)

  4. Determine subject tolerability of the device

    Time frame: Device removal day (10 days +/- 1)

07

Study locations

8 sites
  • Ziekenhuis Oost-Limburg
    Genk, 3600, Belgium
  • UZ Gent
    Gent, 9000, Belgium
  • KBC Zagreb
    Zagreb, 10000, Croatia
  • Jahn Ferenc Hospital
    Budapest, 1204, Hungary
  • National Institute of Oncology
    Budapest, H-112, Hungary
  • Soroka Medical Center
    Beer-Sheva, 85025, Israel
  • Rabin Medical Center
    Petah Tikva, 49100, Israel
  • Assuta Medical Center
    Tel Aviv, 69710, Israel
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2014 to primary completion in Oct 2017, 43 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2014
First posted
Apr 10, 2014
StartActual
Mar 2014
Primary completionActual
Oct 2017
CompletionActual
Oct 2017
Last update
Dec 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02109991
Lead sponsor
Colospan Ltd.
Responsible party
Sponsor
First posted
Apr 10, 2014
Start date
Mar 2014
Primary completion
Oct 2017
Completion
Oct 2017
Last update
Dec 8, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion